Vertex Pharmaceuticals (VRTX) Spikes on Release of Two Studies

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) rose 23.5% to $110.73 after the company disclosed that two Phase 3 studies of the tezacaftor/ivacaftor combo treatment for CF met primary endpoints. BMO Capital upgraded Vertex Pharma from market perform to outperform. Share volume was 7.1 million, compared to an all-day average of 1.6 million